Year archive

BioLineRx Ltd. — 2024 filings

All 83 regulatory filings released by BioLineRx Ltd. (BLRX) in 2024, sourced directly from the official regulator.

83 Filings

2024 Period

2024 filings (83)

Filing	Released	Lang
Form S-8 Share Issue/Capital Change	2024-12-28	English
Form S-8 Regulatory Filings	2024-12-28	English
S-8 Registration Form	2024-12-27	English
6-K Foreign Filer Report	2024-11-25	English
BioLineRx Reports Third Quarter 2024 Financial Results Interim / Quarterly Report Q3 2024	2024-11-25	English
BioLineRx Reports Third Quarter 2024 Financial Results Report Publication Announcement Q3 2024	2024-11-25	English
6-K Foreign Filer Report	2024-11-21	English
424B5 Prospectus	2024-11-21	English
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd Regulatory Filings	2024-11-21	English
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd Report Publication Announcement	2024-11-21	English
PROSPECTUS SUPPLEMENT Capital/Financing Update	2024-11-21	English
PROSPECTUS SUPPLEMENT Capital/Financing Update	2024-11-21	English
The company intends to publish an immediate report about a material event, trading in its shares will resume after the publication of the report Regulatory Filings	2024-11-21	Hebrew (modern)
Received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 12, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement. Regulatory Filings	2024-11-13	English
Received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 12, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement. Report Publication Announcement	2024-11-13	English
6-K Foreign Filer Report	2024-11-12	English
6-K Foreign Filer Report	2024-11-05	English
BioLineRx Announces Oral Presentation at ASH 2024 Regulatory Filings	2024-11-05	English
BioLineRx Announces Oral Presentation at ASH 2024 Report Publication Announcement	2024-11-05	English
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide Regulatory Filings	2024-10-16	English
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide Report Publication Announcement	2024-10-16	English
6-K Foreign Filer Report	2024-10-16	English
Results of the Company’s Annual General Meeting of Shareholders which was held on October 1, 2024 AGM Information	2024-10-06	English
Results of the Company’s Annual General Meeting of Shareholders which was held on October 1, 2024 AGM Information	2024-10-06	English
6-K Foreign Filer Report	2024-10-01	English
Immediate Report of Meeting to be held on October 1, 2024,proxy statement Proxy Solicitation & Information Statement	2024-08-19	English
Immediate Report of Meeting to be held on October 1, 2024,proxy statement AGM Information	2024-08-19	English
Immediate Report of Meeting to be held on October 1, 2024,proxy statement AGM Information	2024-08-19	English
6-K Foreign Filer Report	2024-08-19	English
6-K Foreign Filer Report	2024-08-15	English
Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates Interim / Quarterly Report Q2 2024	2024-08-15	English
Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates Report Publication Announcement	2024-08-15	English
FORM 6-K-A complaint was filed with the District Court of Jerusalem Legal Proceedings Report	2024-06-18	English
FORM 6-K-A complaint was filed with the District Court of Jerusalem Regulatory Filings	2024-06-18	English
6-K Foreign Filer Report	2024-06-18	English
6-K Foreign Filer Report	2024-05-30	English
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio Regulatory Filings	2024-05-30	English
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio Report Publication Announcement	2024-05-30	English
6-K Foreign Filer Report	2024-05-28	English
Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates Interim / Quarterly Report Q1 2024	2024-05-28	English
Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates Earnings Release Q1 2024	2024-05-28	English
Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Regulatory Filings	2024-05-24	English
Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Report Publication Announcement	2024-05-24	English
6-K Foreign Filer Report	2024-05-24	English
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification Regulatory Filings	2024-05-19	English
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification Regulatory Filings	2024-05-19	English
6-K Foreign Filer Report	2024-05-17	English
6-K Foreign Filer Report	2024-05-06	English
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 Regulatory Filings	2024-05-06	English
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 Report Publication Announcement	2024-05-06	English
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting Regulatory Filings	2024-04-17	English
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting Report Publication Announcement	2024-04-17	English
6-K Foreign Filer Report	2024-04-17	English
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement Capital/Financing Update	2024-04-10	English
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement Capital/Financing Update	2024-04-10	English
6-K Foreign Filer Report	2024-04-10	English
Definitive agreement with certain institutional investors providing for the issuance and sale in a registered direct offering of 7,500,000 ADSs and warrants to purchase up to an aggregate of 7,500,00 Regulatory Filings	2024-04-01	English
Definitive agreement with certain institutional investors providing for the issuance and sale in a registered direct offering of 7,500,000 ADSs and warrants to purchase up to an aggregate of 7,500,00 Report Publication Announcement	2024-04-01	English
PROSPECTUS SUPPLEMENT - 7,500,000 ADS and Warrants to Purchase 7,500,000 ADS Capital/Financing Update	2024-04-01	English
PROSPECTUS SUPPLEMENT - 7,500,000 ADS and Warrants to Purchase 7,500,000 ADS Report Publication Announcement	2024-04-01	English
6-K Foreign Filer Report	2024-04-01	English
424B5 Prospectus	2024-04-01	English
Form 20-F/A (Amendment No. 1 Annual Report FY 2023	2024-03-28	English
Form 20-F/A (Amendment No. 1 Report Publication Announcement FY 2023	2024-03-28	English
20-F/A Annual Report FY 2023	2024-03-26	English
Annual Report on Form 20-F FOR 2023 Annual Report FY 2023	2024-03-26	English
Annual Report on Form 20-F FOR 2023 Report Publication Announcement	2024-03-26	English
Annual Report on Form 20-F Earnings Release FY 2023	2024-03-26	English
Annual Report on Form 20-F Report Publication Announcement	2024-03-26	English
20-F Annual Report FY 2023	2024-03-26	English
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates Earnings Release FY 2023	2024-03-26	English
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates Report Publication Announcement	2024-03-26	English
6-K Foreign Filer Report	2024-03-26	English
6-K Foreign Filer Report	2024-03-04	English
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production Regulatory Filings	2024-03-04	English
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production Report Publication Announcement	2024-03-04	English
6-K Foreign Filer Report	2024-02-28	English
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) Regulatory Filings	2024-02-28	English
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) Report Publication Announcement	2024-02-28	English
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meeti Regulatory Filings	2024-02-18	English
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meeti Report Publication Announcement	2024-02-18	English
6-K Foreign Filer Report	2024-02-16	English
Regulatory Filings 2024 Regulatory Filings	2024-01-08	English

Filings by year

2026 22 filings
2025 52 filings
2024 83 filings
2023 63 filings
2022 74 filings
2021 85 filings
2020 136 filings
2019 90 filings
2018 104 filings
2017 152 filings
2016 106 filings
2015 140 filings
2014 159 filings
2013 168 filings
2012 167 filings
2011 65 filings
2010 1 filing